Table 1 Correlation between miR-612 expression and clinicopathologic in HCC patients
From: MiR-612 regulates invadopodia of hepatocellular carcinoma by HADHA-mediated lipid reprogramming
Characteristics | Cases (n = 134) | Relative miR-612 expression | ||
|---|---|---|---|---|
miR-612low (n = 63) | miR-612high (n = 71) | p-valuea | ||
Age (year) | 0.284 | |||
≤ 58 | 70 (52.2%) | 36 | 34 | |
> 58 | 64 (47.8%) | 27 | 37 | |
Sex | 0.790 | |||
Male | 105 (78.4%) | 50 | 55 | |
Female | 29 (21.6%) | 13 | 16 | |
AFP (ng/ml) | 0.136 | |||
≤ 20 | 58 (43.3%) | 23 | 35 | |
> 20 | 76 (56.7%) | 40 | 36 | |
ALT(U/L) | 0.789 | |||
≤ 75 | 115 (85.8%) | 55 | 60 | |
> 75 | 19 (14.2%) | 8 | 10 | |
HBsAg | 0.101 | |||
Negative | 32 (23.9%) | 11 | 21 | |
Positive | 102 (76.1%) | 52 | 50 | |
HCVAb | 0.320 | |||
Negative | 12 (9.0%) | 4 | 8 | |
Positive | 122 (91.0%) | 59 | 63 | |
Liver cirrhosis | 0.647 | |||
No | 32 (23.9%) | 13 | 17 | |
Yes | 101 (75.4%) | 50 | 54 | |
NA | 1 (0.7%) | |||
Tumor size (cm) | 0.002 | |||
< 3 | 21 (15.7%) | 5 | 16 | |
3–5 | 40 (29.9%) | 14 | 26 | |
> 5 | 73 (54.4%) | 44 | 29 | |
NA | 0 | |||
Tumor number | 0.959 | |||
Single | 96 (71.6%) | 45 | 51 | |
Multiple | 38 (28.4%) | 18 | 20 | |
BCLC | 0.045 | |||
A | 14 (10.4%) | 3 | 11 | |
B | 71 (53.0%) | 31 | 40 | |
C | 49 (36.6%) | 29 | 20 | |
NA | 0 | |||
Differentiation | 0.032 | |||
I | 4 (3.0%) | 1 | 3 | |
II | 89 (66.4%) | 40 | 49 | |
III | 41 (30.6%) | 22 | 19 | |
NA | 0 | |||
Tumor thrombus | 0.020 | |||
No | 82 (61.2%) | 32 | 50 | |
Yes | 52 (38.8%) | 31 | 21 | |
NA | 0 | |||
Ascites | 0.553 | |||
No | 129 (96.3%) | 60 | 69 | |
Yes | 5 (3.7%) | 3 | 2 | |
NA | 0 | |||